"The voice for cancer physicians and their patients in Massachusetts."

FDA Broadens Indication and Grants Expanded Approval for Established RET-Targeted Therapy

11 Oct 2022 10:36 AM | Katy Monaco (Administrator)

Lilly USA, LLC is pleased to announce recent major label changes for Retevmo® (selpercatinib, 80 mg and 40 mg capsules). Read press release here

Massachusetts Society of Clinical Oncologists ©2022

860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329  |  Fax: 781.464.4896  |  email: msco@mms.org

Powered by Wild Apricot Membership Software